Pulmonary artery hypertension: an underrated disease manifestation in cystic fibrosis?
Relapsing pancreatitis as initial manifestation of cystic fibrosis in a young man without pulmonary disease.
Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype.
Cystic Fibrosis.
Dickinson KM, Collaco JM.
Pediatr Rev. 2021 Feb;42(2):55-67. doi: 10.1542/pir.2019-0212.
Cystic Fibrosis: A Review.
Ong T, Ramsey BW.
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
Cystic fibrosis.
Shteinberg M, Haq IJ, Polineni D, Davies JC.
Lancet. 2021 Jun 5;397(10290):2195-2211. doi: 10.1016/S0140-6736(20)32542-3.
Cystic fibrosis: current concepts.
López-Valdez JA, Aguilar-Alonso LA, Gándara-Quezada V, Ruiz-Rico GE, Ávila-Soledad JM, Reyes AA, Pedroza-Jiménez FD.
Bol Med Hosp Infant Mex. 2021;78(6):584-596. doi: 10.24875/BMHIM.20000372.
Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement.
Agarwala P, Salzman SH.
Chest. 2020 Mar;157(3):603-611. doi: 10.1016/j.chest.2019.10.014. Epub 2019 Nov 2.
Cystic Fibrosis: Pathophysiology of Lung Disease.
Bergeron C, Cantin AM.
Semin Respir Crit Care Med. 2019 Dec;40(6):715-726. doi: 10.1055/s-0039-1694021. Epub 2019 Oct 28.
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
Regard L, Martin C, Burnet E, Da Silva J, Burgel PR.
Cells. 2022 May 28;11(11):1769. doi: 10.3390/cells11111769.
The future of cystic fibrosis care: a global perspective.
Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F.
Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27.
Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment.
Brown SD, White R, Tobin P.
JAAPA. 2017 May;30(5):23-27. doi: 10.1097/01.JAA.0000515540.36581.92.
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ahluwalia N, Chin A, Chu C, Lu M, Menon P, Waltz D, Weinstock T, Zelazoski L, Davies JC.
Am J Respir Crit Care Med. 2023 Jul 1;208(1):68-78. doi: 10.1164/rccm.202301-0021OC.
